A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of UTTR1147A Compared With Placebo and With Vedolizumab in Participants With Moderate to Severe Ulcerative Colitis (UC)
- Ulcerative Colitis
Trial Status:
Completed
This trial runs in
Cities
- ballinasloe
- Beograd
- Berlin
- Budapest
- Bydgoszcz
- cascina-perseghetto
- Chernivtsi
- Chișinău
- Częstochowa
- Dnipro
- Dnipropetrovs'k
- Dresden
- Düsseldorf
- Elizabeth City
- Gdańsk
- Girona
- Great Neck
- Greenville
- Irkutsk
- Jerusalem
- Katowice
- Kielce
- Kragujevac
- Kropyvnytskyi
- Kyiv
- Las Palmas de Gran Canaria
- London
- Lublin
- Ludwigshafen am Rhein
- Lübeck
- Madrid
- Monza
- Nashville
- Nowy Targ
- Padova
- Palaio Faliro
- Piotrków Trybunalski
- Plovdiv
- Poznań
- Roma
- Rostov
- Salt Lake City
- Samara
- Sankt-Peterburg
- Sliven
- Sofia
- Sopot
- Stara Zagora
- Ternopil
- Thessaloniki
- Torrejón de Ardoz
- Toruń
- Ulm
- Uzhhorod
- Vinnytsia
- Vršac
- Warsaw
- Warszawa
- Wrocław
- Zaporizhzhia
- Zhytomyr
- Zrenjanin
- Łódź
Trial Identifier:
NCT03558152 2017-002350-36 GA39925
Trial Summary
This study is designed to evaluate the efficacy, safety, and pharmacokinetics of UTTR1147A compared with vedolizumab and with placebo in the treatment of participants with moderate to severe UC. This study will consist of two parts, Part A and Part B. Part A will test the induction of clinical remission and Part B will test the durability of clinical remission.
Genentech, Inc.
Sponsor
Phase 2
Phase
NCT03558152 , GA39925 , 2017-002350-36
Trial Identifier
UTTR1147A, UTTR1147A Placebo, Vedolizumab, Vedolizumab Placebo
Treatments
Ulcerative Colitis
Condition
Official Title
A Phase II, Randomized, Parallel-Group, Double-Blind, Double-Dummy, Placebo-Controlled, Multicenter Study To Evaluate the Efficacy, Safety, and Pharmacokinetics of UTTR1147A Compared With Placebo and Compared With Vedolizumab in Patients With Moderate to Severe Ulcerative Colitis
Eligibility Criteria
All
Gender
≥ 18 Years & ≤ 80 Years
Age
No
Healthy Volunteers
Inclusion Criteria
- Diagnosis of UC
- Confirmation of moderately to severely active UC, defined by the Mayo Clinic Score
- Inadequate response, loss of response, or intolerance to prior immunosuppressant treatment (i.e., azathioprine, 6-mercaptopurine, methotrexate, or tumor necrosis factor [TNF] inhibitors [maximum of 2 prior TNF inhibitors]) and/or corticosteroid treatment
- Use of highly effective contraception as defined by the protocol
Exclusion Criteria
- History of psoriasis or psoriatic arthritis; any other inflammatory skin disorders requiring oral corticosteroids, immunosuppressants, or biological therapy within the previous year; or primary sclerosing cholangitis
- History of cancer as defined by the protocol
- Significant uncontrolled comorbidity, such as cardiac, pulmonary, renal, hepatic, endocrine, or gastrointestinal disorders (excluding UC)
- Prior extensive colonic resection, subtotal or total colectomy, or proctocolectomy, or planned surgery for UC
- Diagnosis of indeterminate colitis or granulomatous (Crohn's) colitis or toxic megacolon within 12 months prior to screening
- Suspicion of ischemic colitis, radiation colitis, or microscopic colitis
- Current fistula or history of fistula, pericolonic abscess and stricture (stenosis) of the colon
- History or current evidence of unresectable colonic mucosal dysplasia or history of high-grade colonic mucosal dysplasia
- Prior treatment with UTTR1147A
- Prior treatment with vedolizumab, etrolizumab, natalizumab, efalizumab, or any other anti-integrin agents
- Prior treatment with rituximab
- Use of prohibited therapies, as defined by the protocol, prior to randomization
- Congenital or acquired immune deficiency
- Evidence or treatment of infections or history of infections, as defined by the protocol
For the latest version of this information please go to www.forpatients.roche.com